WO2003055545A1 - Adsorbant de cytokine, procede d'elimination par adsorption et appareil correspondant - Google Patents
Adsorbant de cytokine, procede d'elimination par adsorption et appareil correspondant Download PDFInfo
- Publication number
- WO2003055545A1 WO2003055545A1 PCT/JP2002/013207 JP0213207W WO03055545A1 WO 2003055545 A1 WO2003055545 A1 WO 2003055545A1 JP 0213207 W JP0213207 W JP 0213207W WO 03055545 A1 WO03055545 A1 WO 03055545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adsorbent
- cytokine
- water
- group
- carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28016—Particle form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28016—Particle form
- B01J20/28021—Hollow particles, e.g. hollow spheres, microspheres or cenospheres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28023—Fibres or filaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3092—Packing of a container, e.g. packing a cartridge or column
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3255—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/58—Use in a single column
Definitions
- the present invention relates to the production of interleukin-14 (hereinafter referred to as IL-4), interleukin-10 (hereinafter referred to as IL-10) and interleukin-13 (hereinafter referred to as IL-13) from body fluids.
- the present invention relates to an adsorbent for adsorbing and removing at least one cytokine selected from the group consisting of: a method for adsorbing and removing cytokines using the same; and an adsorber for the cytokine.
- cytokines proteinaceous substances
- cytokines proteinsaceous substances
- Cytokines are essentially essential for maintaining homeostasis in living organisms, but are produced in excess in conditions such as inflammation and are involved in the formation and prolongation of inflammation.
- I-4 is a substance reported as a factor that activates B cells by Howard and Paul in 1998 and by Vita et al. Later, it was clarified to act on cells other than B cells, and the name was changed to IL-4.
- IL-14 is a glycoprotein with a molecular weight of 20 kDa. T cells and mast cells are known as IL-14 producing cells.
- IL-14 The functions of IL-14 include activation of B cells, induction of differentiation and proliferation, induction of T cell proliferation and differentiation into Th2 cells, induction of thymocyte proliferation, induction of NK cell and LAK cell activation, Eosinophilic anti-tumor effect, macrophage anti-inflammatory effect, mast cell proliferation induction
- induction fibroblasts, enhancement of vascular endothelial cell adhesion molecule expression, and promotion of hematopoietic cell colony formation.
- IL-110 is a substance identified in 1989 by Mosmaim et al. As a factor that suppresses cytokine production. Initially, IL-10 was called a cytodynamic factor, but it was found to have various other activities and was renamed IL-10. IL-10 is a homodimeric glycoprotein with a molecular weight of 35 to 40 kDa. Known IL_10 producing cells include Th0 / Th2 cells, activated T cells, monocyte Z macrophages, activated B cells, melanocytes, and the like. Functions of IL-10 include suppression of IFN-alpha production from T cells, induction of T cell proliferation, induction of B cell proliferation, enhancement of monocyte ADCC activity, and monocyte Z There is one type of monokine production suppression.
- I L-13 is a substance cloned in 1993 by Minty et al. Of France and Brown et al. Of the United States.
- the IL-13 gene is introduced into COS cells, it is expressed as a glycoprotein with a molecular weight of 17 kDa.
- Activated T cells are known as cells producing IL-11.
- IL-113 functions include suppression of inflammatory cytokine production in monocytes stimulated with LPS, prolonged survival of monocytes, and induction of CD23 and MHC class II expression on monocyte and B cell surfaces. There is something.
- site forces such as IL-14, IL-10, and IL-13
- site forces are called anti-inflammatory site forces, and their functions include macrophage anti-inflammatory effects and suppression of monocyte / macrophage monoforce in production. It has an anti-inflammatory effect, such as suppression of the production of inflammatory cytokines in monocytes stimulated with LPS.
- IL-1 interleukin-1
- IL-6 interleukin-1 6
- IL-18 interleukin-1 8
- TNF- ⁇ tumor dying factor- ⁇
- Anti-inflammatory cytokines have been reported to suppress the action of these inflammatory cytokines. Recently, however, there has been a disease state that is encompassed by the concept of compensatory anti-inflammatory response syndrome (CARS). As a result, excessive anti-inflammatory site forces are produced, resulting in suppression of the immune response and a susceptibility to infection. Therefore, organ infection may occur in the case of infection such as sepsis.
- CARS compensatory anti-inflammatory response syndrome
- cytokines are supposed to work locally, and an increase in blood concentration is not desirable for the human body. Therefore, a method for removing these cytokines from blood is desired.
- Adsorbents for removing IL-1, IL-16, IL-18 and TNF- ⁇ which are called inflammatory cytokines
- inflammatory cytokines Adsorbents for removing IL-1, IL-16, IL-18 and TNF- ⁇ , which are called inflammatory cytokines
- Japanese Patent Application Laid-Open Nos. 08-257115 and 08-257398 Japanese Patent Application Laid-Open Nos. 08-257115 and 08-257398.
- these inflammatory cytokines can be adsorbed and removed by an adsorbent obtained by immobilizing a compound having a lgP value of at least 2.50 on a water-insoluble carrier.
- an adsorbent comprising a compound having a ogP value of at least 2.50 immobilized on the water-insoluble carrier, wherein an anti-inflammatory cytokine having a bioactive property of inflammation that is exactly opposite to that of the inflammatory cytokine. It has been newly found that adsorption can be removed.
- the present inventors have intensively studied an adsorbent capable of efficiently adsorbing and removing at least one cytokine selected from the group consisting of IL_4, IL-10 and IL-13 in a body fluid.
- the adsorbent obtained by immobilizing a compound having a logP value of 2.50 or more on a water-insoluble carrier is at least one type selected from the group consisting of IL-14, IL-10, and IL-13 in a body fluid.
- the present inventors have found that cytokine can be efficiently adsorbed and removed, and completed the present invention.
- the present invention relates to a group consisting of IL-14, IL-10, and IL-13 obtained by immobilizing a compound having a value of 1 og P (P is a partition coefficient of an octanolulu aqueous system) of 2.50 or more on a water-insoluble carrier. At least one site selected from the group consisting of force-in adsorbents.
- the water-insoluble carrier is a water-insoluble porous carrier.
- the present invention provides a method for preparing a compound having an og P (partition coefficient in an octanolulu water system) of 2.50 or more immobilized on a water-insoluble carrier, comprising IL-4, IL-10, and IL-13. At least one selected from the group consisting of IL-14, IL-10 and IL-13 in a body fluid, wherein the body fluid is brought into contact with at least one kind of cytokine adsorbent selected from the group consisting of: And a method for removing cytokines.
- og P partition coefficient in an octanolulu water system
- the present invention provides a water-insoluble carrier in a container having a liquid inlet and an outlet and having a means for preventing the adsorbent from flowing out of the container.
- a compound with a fixed value of 2.50 or more The present invention relates to the at least one cytokine adsorber, which is filled with at least one cytokine adsorbent selected from the group consisting of IL-4, IL-10 and IL-13.
- FIG. 1 is a schematic sectional view of one embodiment of the cytokine adsorber of the present invention.
- 1 is a liquid inlet
- 2 is a liquid outlet
- 3 is a cytokine adsorbent of the present invention
- 4 and 5 are liquids and components contained in the liquid that can pass therethrough, but the site force-in adsorbent Indicates a filter that cannot pass
- 6 indicates a column
- 7 indicates a cytokine adsorber.
- FIG. 2 is a graph showing the results of examining the relationship between flow velocity and pressure loss using three types of materials.
- IL-14 is a glycoprotein having a molecular weight of about 20 kDa.
- IL — 10 is a homodimeric glycoprotein having a molecular weight of about 35 to 40 kDa.
- IL-13 is a glycoprotein having a molecular weight of about 17 kDa.
- the body fluid refers to blood, plasma, serum, ascites, lymph, joint fluid, fraction components obtained therefrom, and other liquid components derived from living bodies.
- the adsorbent of the present invention is obtained by immobilizing a compound having a value of at least 2.5 ⁇ 50 on a water-insoluble porous carrier.
- the log P value is the parameter of the hydrophobicity of a compound, and the distribution coefficient P in a typical water-soluble water system is calculated as follows. Can be First, dissolve the compound in octanol (or water), add an equal amount of water (or octanol), and add the Griffin flask shaker (Griffin and George Limited). (Manufactured by Griffin & George Ltd.) for 30 minutes.
- the concentration of each compound in the octanol layer and the aqueous layer is measured at room temperature and atmospheric pressure by various methods such as spectroscopy or GLC to obtain the following formula. Required from.
- the adsorbent of the present invention is obtained by immobilizing a compound having a 1 gP value of 2.50 or more determined as described above on a water-insoluble carrier.
- Hydrophobic Fragment constant is a value that indicates the hydrophobicity of various fragments determined by statistical processing based on a large number of 1 ogP measured values, and is the sum of the f-values of each fragment constituting the compound. Reported almost coincident with the 1 o gP value. It has been tell.
- the site force-in adsorption by the adsorbent of the present invention is based on the hydrophobic interaction between the atomic group introduced on the carrier by the immobilization of the compound having a og P value of 2.50 or more and the cytokine. It is thought to be due to:
- any compound having a log P value of at least 2.50 can be used without particular limitation.
- a compound is bonded to a carrier by a chemical bonding method, a part of the compound is often eliminated.
- the compound is not suitable as the compound used in the present invention.
- the atomic group actually fixed on the carrier is C 6 H 5 CO—, and the ⁇ f of this atomic group is 1 or less.
- Such compounds include n-heptylamine, n-octylamine, decylamine, dodecylamine, hexadecylamine, octadecylamine, 2-aminooctene, naphthylamine, phenyl n-propylamine, diphenylmethylamine.
- Amines such as min, n-heptyl alcohol, n-octyl alcohol, dodecyl alcohol, hexadecyl alcohol, 1-octen-3-ol, naphthol, diphenylmethanol, 4-phenyl-2-butanol, etc.
- Alcohols and glycidyl ethers of these alcohols n-octanoic acid, nonanoic acid, 2-nonenoic acid, decanoic acid, dodecanoic acid, stearic acid, arachidonic acid, oleic acid, diphenylacetic acid, phenylpropionic acid, etc.
- Acids and Carboxylic acid derivatives such as acid halides, esters, and amides; halides such as octyl chloride, octyl bromide, decyl chloride, and dodecyl chloride; thiols such as octanethiol and dodecanethiol; and n-octyltrichlorosilane And halogenated silanes such as octadecyltrichlorosilane, and aldehydes such as n-octylaldehyde, n_force purine aldehyde and dodecyl aldehyde.
- halides such as octyl chloride, octyl bromide, decyl chloride, and dodecyl chloride
- thiols such as octanethiol and dodecanethiol
- Each of these compounds may be used alone, or two or more of them may be used in combination. Further, they may be used in combination with a compound having a log P value of less than 2.5.
- the water-insoluble carrier in the adsorbent of the present invention means that it is solid at normal temperature and normal pressure and water-insoluble.
- the water-insoluble carrier in the present invention may be in the form of granules, plates, fibers, hollow fibers, or the like, but the shape is not limited, and the size is not particularly limited.
- the average particle size is preferably 5 m or more and 100 Im or less. If the average particle size is smaller than 5 x m, there is a tendency that when the body fluid contains cells, there is not enough space for cells to pass through. If the average particle diameter exceeds 100 / m, sufficient adsorption capacity per volume tends not to be obtained.
- the average particle size is more preferably 25 m or more and 100 m or less from the viewpoint that cells can pass smoothly, and is 40 m or more and 600 m from the viewpoint of easier passage of cells and adsorption ability. The following are particularly preferred.
- the average particle size is preferably 200 m or more and 100 m or less from the viewpoint of easy passage of blood cells, and 200 m or less from the viewpoint of obtaining the adsorbing ability. More preferably xm or more and 600 / zm or less. In addition, it is preferable that the particle size distribution is narrow because it does not cause an increase in pressure loss.
- the inner diameter is preferably not less than m and not more than 500 zm. If the inner diameter is smaller than 1 m, the cells tend not to pass sufficiently when the body fluid contains cells. If the inner diameter exceeds 500 m, the adsorption capacity per volume tends to be insufficient.
- the inner diameter is more preferably 2 ⁇ m or more and 500m or less from the viewpoint that cells can smoothly pass therethrough. To 5 ⁇ m or more and 200 m or less.
- water-insoluble carrier in the adsorbent of the present invention examples include inorganic carriers such as glass beads and silica gel, synthetic polymers such as cross-linked polyvinyl alcohol, cross-linked polyacrylate, cross-linked polyacrylamide, and cross-linked polystyrene, crystalline cellulose, and cross-linked cellulose.
- inorganic carriers such as glass beads and silica gel
- synthetic polymers such as cross-linked polyvinyl alcohol, cross-linked polyacrylate, cross-linked polyacrylamide, and cross-linked polystyrene, crystalline cellulose, and cross-linked cellulose.
- organic carriers composed of polysaccharides such as cross-linked agarose and cross-linked dextrin
- composite carriers such as organic-organic and organic-inorganic obtained by combining these.
- hydrophilic carriers are preferred because non-specific adsorption is relatively small and adsorption selectivity of site force-in is good.
- the hydrophilic carrier refers to a carrier having a contact angle of water of 60 degrees or less when a compound constituting the carrier is formed into a plate.
- Various methods of measuring the contact angle of water are known. For example, Ikeda's book (Experimental Chemical Selection, Colloid Chemistry, Chapter 4, Interface Thermodynamics, pp. 75-104, Shokabo) As shown in (1966)), the most common method is to place a water drop on a compound plate and measure.
- Compounds having a contact angle of water of 60 ° or less as measured by the above method include cellulose, polyvinyl alcohol, saponified ethylene-vinyl acetate copolymer, polyacrylamide, polyacrylic acid, polymethacrylic acid, and poly (methacrylic acid).
- Representative examples include carriers composed of methyl methacrylate, polyacrylic acid-grafted polyethylene, polyacrylamide-grafted polyethylene, glass, and the like.
- these water-insoluble carriers have a large number of pores of an appropriate size, that is, a carrier having a porous structure.
- the carrier having a porous structure includes not only a carrier having a space (macropore) formed by agglomeration of microspheres when a basic polymer matrix forms one spherical particle by aggregation of microspheres, A carrier with pores formed between nuclei in one microsphere constituting the basic polymer matrix or a copolymer with a three-dimensional structure (polymer network) has affinity Exists when swollen by a certain organic solvent Carriers having pores (micropores) are included.
- the water-insoluble carrier having a porous structure is preferably totally porous rather than surface porous, and the pore volume and specific surface area impair the adsorbability. It is preferable that it is not so large.
- Porous cellulose gel As a carrier satisfying these preferable requirements, a porous cellulose gel can be mentioned.
- Porous cellulose gel has relatively high mechanical strength and is hardly broken or generates fine powder due to operation such as stirring. Is not condensed, so that it can be flowed at a high flow rate, and the pore structure is not easily changed by high-pressure steam sterilization, etc.
- It is hydrophilic because the gel is composed of cellulose, There are many hydroxyl groups that can be used for ligand binding, and non-specific adsorption is small.
- It has excellent features such as higher safety than synthetic polymer gels and the like, and is one of the most suitable carriers used in the present invention.
- the present invention is not limited only to these, and the above-mentioned carriers may be used alone or in any combination of two or more.
- the water-insoluble carrier having such a porous structure allows the substance to be adsorbed to penetrate into the pores with a certain degree of probability, but more preferably has the characteristic that penetration of other proteins does not occur as much as possible.
- IL-4 to be adsorbed by the adsorbent of the present invention is a protein having a molecular weight of about 20 kDa
- IL-10 is a protein having a molecular weight of about 35 to 40 kDa.
- 3 is a protein with a molecular weight of about 17 kDa, in order to adsorb these proteins efficiently, the cytokine can penetrate into the pores with a certain probability, but other proteins can penetrate It is more preferable that this does not occur as long as possible.
- Bound molecular weight is commonly used. As described in a compendium (eg, Hiroyuki Hatano and Toshihiko Hanai, Experimental High-Performance Liquid Chromatography, Chemical Doujinshi) etc., it is impossible to penetrate into pores by gel permeation mouth chromatography (excluded). ) The molecular weight of the molecule with the smallest molecular weight.
- the exclusion limit molecular weight is generally well investigated for globular proteins, dextran, polyethylene glycol and the like.
- the carrier used in the present invention it is appropriate to use the values obtained using globular proteins.
- the range of the exclusion limit molecular weight of the globular protein suitable for the adsorption of the cytokine is 5,000 to 600,000. That is, when a carrier having an exclusion limit molecular weight of globular protein of less than 5,000 is used, the adsorption amount of the cytokine is small and its practicality is reduced. Adsorption of other proteins (mainly albumin) is increased, and its utility is reduced in selectivity.
- the exclusion limit molecular weight of the globular protein of the carrier used in the present invention is preferably 5,000 or more and 600,000 or less. From the viewpoint of obtaining more effective adsorption amount and selectivity, 6,000 or more and 400,000 or less are more preferable, and 10,000 or more and 300,000 or less are most preferable.
- the carrier preferably has a functional group that can be used for the reaction for immobilizing the ligand.
- these functional groups include a hydroxyl group, an amino group, an aldehyde group, a propyloxyl group, a thiol group, a silanol group, an amide group, an epoxy group, a halogen group, a succinilimide group, and an acid anhydride group. But not limited to these.
- the carrier used in the present invention is hard. More preferably, it is a carrier.
- the term "hard carrier” used herein refers to, for example, in the case of a granular gel, as shown in Reference Examples below, where the gel is uniformly filled in a cylindrical column, and the relationship between the pressure loss ⁇ P and the flow rate when flowing an aqueous fluid is 0. It refers to what is in linear relationship up to 3 kg / cm 2.
- the adsorbent of the present invention can be obtained by immobilizing a compound having a 1 og P value of 2.50 or more on a water-insoluble porous carrier, and various known methods can be used for immobilization without any particular limitation. Can be. However, when the adsorbent of the present invention is used for extracorporeal circulation treatment, it is important for safety to minimize the desorption and elution of the ligand during sterilization or treatment, and for this purpose, it is immobilized by covalent bonding. Is preferred.
- the amount of the compound having a 1 og P value of 2.50 or more in the adsorbent of the present invention is preferably 1 o 1 / g—wet weight or more and 5000 / xmol / g—wet weight or less. If the fixed amount is less than 1 zmolZg—wet weight, the adsorption of the site force tends to be insufficient. When the fixed amount exceeds 5000 umol lZg—wet weight, if the liquid is blood, there is a tendency for sticking of platelets and the like to occur. From the viewpoint of effective adsorption capacity and less adhesion of platelets, more preferably 5 mo 1 Zg—wet weight or more and 3000 ⁇ mo 1 / g—wet weight or less.
- the simplest method is to take out the body fluid, store it in a bag or the like, mix it with an adsorbent to adsorb and remove the site force, and then filter off the adsorbent to obtain a body fluid from which the cytokine has been removed.
- the next method has a body fluid inlet and an outlet, and there is a method in which an absorbent is filled in a container equipped with a filter through which the body fluid passes but the adsorbent does not pass, and the body fluid flows into the container.
- Either method can be used, but the latter method is easy to operate, and can be integrated into the extracorporeal circuit to control the patient.
- the cytokine can be efficiently and efficiently removed from body fluids, particularly blood, online, and the adsorbent of the present invention is suitable for this method.
- the adsorbent of the present invention can be used alone in the extracorporeal circulation circuit, but can be used in combination with another extracorporeal circulation treatment system.
- Examples of the combination include an artificial dialysis circuit and the like, and can be used in combination with dialysis therapy.
- FIG. 1 is a schematic sectional view of one embodiment.
- 1 is a liquid inlet
- 2 is a liquid outlet
- 3 is a cytokine adsorbent of the present invention
- 4 and 5 are liquids and components contained in the liquid can pass, but the cytokine adsorbent passes. Filters that cannot be used, 1 indicates a column, and 7 indicates a sight force-in adsorber.
- the site force-in adsorber is not limited to such a specific example, and is provided in a container having a liquid inlet and an outlet, and having a device for preventing the site force-in adsorbent from flowing out of the container. Any material may be used as long as it is filled with the adsorbent.
- Examples of the outflow prevention device include a filter such as a mesh, a nonwoven fabric, and a cotton plug.
- the shape, material, and size of the container are not particularly limited, but the shape is preferably a cylindrical container.
- the material of the container is preferably a material having sterilization resistance, and specific examples include silicon-coated glass, polypropylene, polyvinyl chloride, polyacrylonitrile, polysulfone, and polymethylpentene.
- the capacity of the container is preferably 5 Oml or more and 150 Om1 or less, and the diameter is preferably 2 cm or more and 2 Ocm or less.
- the capacity of the container is smaller than 50 m1, the amount of adsorption is not sufficient, and if it is larger than 150 Om1, the extracorporeal circulation increases, which is not preferable.
- the diameter of the vessel is smaller than 2 cm, the linear velocity increases and the pressure loss increases, which is not preferable. If it is larger than 20 cm, it will be difficult to handle and the linear velocity will be low, so there is a risk of coagulation and it is preferable. Not good.
- the capacity is 100 m1 or more and 800 ml or less, and the diameter is more preferably 3 cm or more and 15 cm or less, and the capacity is more than 15 Oml and 400 ml or less in terms of effective adsorption amount and excellent safety.
- the diameter is particularly preferably 4 cm or more and 10 cm or less.
- Bioge 1 A_5m causes consolidation and increases the pressure. It can also be seen that the flow rate does not increase.
- a material in which the relationship between the pressure loss ⁇ and the flow rate has a linear relationship up to 0.3 kg / cm 2 is called a hard material.
- an adsorption experiment was performed in the same manner as in Example 1, and the concentration of each cytokine was determined. was measured. Table 1 shows the results.
- an adsorption experiment was performed in the same manner as in Example 1, and the concentration of each cytokine was measured. Table 1 shows the results.
- Cellulose acetate is dissolved in a mixed solvent of dimethyl sulfoxide and propylene glycol, and this solution is formed into droplets by the method (vibration method) described in JP-A-63-117039, and solidified. Spherical hydrogel particles of cellulose acetate were obtained. The hydrogel particles are mixed with an aqueous sodium hydroxide solution. The resulting mixture was subjected to a hydrolysis reaction to obtain cellulose hydrogel particles (average particle size: 460 ⁇ m, molecular weight exclusion limit of globular protein: 50,000).
- n_hexadecylamine immobilized amount 35/1 molZg —Wet weight
- Particles immobilized with n-hexylamine were obtained in the same manner as in Example 3, except that n-hexadecylamine was replaced with n-yearly octylamine, and the medium for the immobilization reaction was changed from ethanol to a 50 (v / v)% aqueous ethanol solution. (N-fixed amount of octylamine: 33 ⁇ mo 1 / g-wet weight). Using the immobilized particles, an adsorption experiment was performed in the same manner as in Example 1, and the site force-in concentration was measured. Table 2 shows the results.
- Example 2 An adsorption experiment was carried out in the same manner as in Example 1 using the hydrogel particles of the cell mouth having no ligand immobilized thereon prepared in Example 3, and the concentration of each cytokine was measured. Table 2 shows the results. Table 2
- the carrier is selected from the group consisting of IL-4, 1-10 and 1-13. At least one cytokine can be efficiently adsorbed and removed.
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02805884A EP1466636A4 (en) | 2001-12-25 | 2002-12-18 | "Adsorptive Agent for Cytokine, Method for Adsorptive Removal and Device for Adsorptive Separation" |
JP2003556120A JPWO2003055545A1 (ja) | 2001-12-25 | 2002-12-18 | サイトカインの吸着材、吸着除去方法および吸着除去装置 |
US10/499,791 US20050063935A1 (en) | 2001-12-25 | 2002-12-18 | Adsorbent for cytokine, method of adsorptive removal, and apparatus adsorptive removal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-391136 | 2001-12-25 | ||
JP2001391136 | 2001-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003055545A1 true WO2003055545A1 (fr) | 2003-07-10 |
Family
ID=19188485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/013207 WO2003055545A1 (fr) | 2001-12-25 | 2002-12-18 | Adsorbant de cytokine, procede d'elimination par adsorption et appareil correspondant |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050063935A1 (ja) |
EP (1) | EP1466636A4 (ja) |
JP (1) | JPWO2003055545A1 (ja) |
WO (1) | WO2003055545A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008237893A (ja) * | 2007-02-22 | 2008-10-09 | Toray Ind Inc | 血液処理カラム |
JP2009178523A (ja) * | 2008-02-01 | 2009-08-13 | Kaneka Corp | 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置 |
JP2016107262A (ja) * | 2014-11-27 | 2016-06-20 | 国立大学法人佐賀大学 | エンドトキシン及び/又はサイトカインの吸着体及びその製造方法、これを配合した皮膚外用製剤及び経口投与用製剤、並びにエンドトキシン及び/又はサイトカインの吸着除去方法 |
WO2020203927A1 (ja) * | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
WO2020203923A1 (ja) * | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102134230B (zh) * | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
RU2749419C2 (ru) * | 2016-09-09 | 2021-06-09 | Торэй Индастриз, Инк. | Материал для очистки крови |
MY196606A (en) | 2017-06-06 | 2023-04-20 | Toray Industries | Material For Removing Activated Leukocyte-Activated Platelet Complex |
EP4007618A1 (en) * | 2019-08-01 | 2022-06-08 | Sigyn Therapeutics, Inc. | Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009396A1 (fr) * | 1989-02-08 | 1990-08-23 | Kuraray Co., Ltd. | Peptide et adsorbant le comprenant immobilise sur un support |
JPH08257398A (ja) | 1995-01-27 | 1996-10-08 | Kanegafuchi Chem Ind Co Ltd | インターロイキン類の吸着剤および吸着除去方法 |
JPH08257115A (ja) | 1995-03-20 | 1996-10-08 | Kanegafuchi Chem Ind Co Ltd | 腫瘍壊死因子の吸着剤および吸着除去方法 |
JPH09501066A (ja) * | 1993-03-16 | 1997-02-04 | ロン―ポレンク ローラー ファーマシューティカルズ インコーポレイテッド | 全血またはその成分からの選択された因子の除去 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2167872C (en) * | 1995-01-27 | 2007-04-03 | Masaru Nakatani | Adsorbent for removing interleukins and tumor necrosis factor, and process for removing the same |
JPH10290833A (ja) * | 1997-04-21 | 1998-11-04 | Kanegafuchi Chem Ind Co Ltd | トキシックショックシンドロームトキシン−1の吸着剤、その吸着除去方法および該吸着剤を充填してなる吸着器 |
-
2002
- 2002-12-18 JP JP2003556120A patent/JPWO2003055545A1/ja active Pending
- 2002-12-18 WO PCT/JP2002/013207 patent/WO2003055545A1/ja active Application Filing
- 2002-12-18 EP EP02805884A patent/EP1466636A4/en not_active Withdrawn
- 2002-12-18 US US10/499,791 patent/US20050063935A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009396A1 (fr) * | 1989-02-08 | 1990-08-23 | Kuraray Co., Ltd. | Peptide et adsorbant le comprenant immobilise sur un support |
JPH09501066A (ja) * | 1993-03-16 | 1997-02-04 | ロン―ポレンク ローラー ファーマシューティカルズ インコーポレイテッド | 全血またはその成分からの選択された因子の除去 |
JPH08257398A (ja) | 1995-01-27 | 1996-10-08 | Kanegafuchi Chem Ind Co Ltd | インターロイキン類の吸着剤および吸着除去方法 |
JPH08257115A (ja) | 1995-03-20 | 1996-10-08 | Kanegafuchi Chem Ind Co Ltd | 腫瘍壊死因子の吸着剤および吸着除去方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008237893A (ja) * | 2007-02-22 | 2008-10-09 | Toray Ind Inc | 血液処理カラム |
JP2009178523A (ja) * | 2008-02-01 | 2009-08-13 | Kaneka Corp | 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置 |
JP2016107262A (ja) * | 2014-11-27 | 2016-06-20 | 国立大学法人佐賀大学 | エンドトキシン及び/又はサイトカインの吸着体及びその製造方法、これを配合した皮膚外用製剤及び経口投与用製剤、並びにエンドトキシン及び/又はサイトカインの吸着除去方法 |
WO2020203927A1 (ja) * | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
WO2020203923A1 (ja) * | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
TWI776136B (zh) * | 2019-03-29 | 2022-09-01 | 日商旭化成醫療股份有限公司 | 血液淨化器 |
TWI782263B (zh) * | 2019-03-29 | 2022-11-01 | 日商旭化成醫療股份有限公司 | 血液淨化器 |
JP7397856B2 (ja) | 2019-03-29 | 2023-12-13 | 旭化成メディカル株式会社 | 血液浄化器 |
JP7397857B2 (ja) | 2019-03-29 | 2023-12-13 | 旭化成メディカル株式会社 | 血液浄化器 |
Also Published As
Publication number | Publication date |
---|---|
EP1466636A1 (en) | 2004-10-13 |
US20050063935A1 (en) | 2005-03-24 |
EP1466636A4 (en) | 2009-06-10 |
JPWO2003055545A1 (ja) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7279106B2 (en) | Adsorbent and method for adsorbing a chemokine in body fluid | |
JP4283430B2 (ja) | エンテロトキシンの吸着材、吸着除去方法および吸着器 | |
US6844427B2 (en) | Method for removing the transforming growth factor-β by adsorption | |
US5919898A (en) | Absorbent for removing interleukins and tumor necrosis factor, and process for removing the same | |
US6315907B1 (en) | Method for removing toxic shock syndrome toxin-1 in body fluids by adsorption | |
WO2003055545A1 (fr) | Adsorbant de cytokine, procede d'elimination par adsorption et appareil correspondant | |
EP0819439B1 (en) | Apparatus comprising an adsorbent for adsorptive elimination of disease-related factors in body fluids | |
JP3901214B2 (ja) | インターロイキン類の吸着剤,吸着除去方法および吸着器 | |
JP3410849B2 (ja) | インターロイキン類の吸着剤および吸着除去方法 | |
JP4035191B2 (ja) | ケモカインの吸着材、吸着除去方法および吸着器 | |
JPH08257115A (ja) | 腫瘍壊死因子の吸着剤および吸着除去方法 | |
JP4859520B2 (ja) | 血圧降下性ペプチドの吸着材、吸着方法および吸着装置 | |
JP2009178523A (ja) | 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置 | |
JPH0528151B2 (ja) | ||
JP3308034B2 (ja) | 糖化変性タンパク質吸着体 | |
JP2007029511A (ja) | ハイモビリティーグループ蛋白の吸着材、吸着方法および吸着装置 | |
JP2006320729A (ja) | トキシックショックシンドロームトキシン−1の吸着剤、該吸着剤の使用および該吸着剤を充填してなる吸着器 | |
JP4777554B2 (ja) | 内因性カンナビノイドの吸着材、吸着除去方法および吸着器 | |
JPS6377457A (ja) | 体外循環治療用の免疫グロブリンl鎖吸着体 | |
JP4837221B2 (ja) | 強心配糖体の吸着材、吸着除去方法および吸着器 | |
JPH04244231A (ja) | 体外循環治療用の補体の活性化抑制材 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): DE FR GB IT |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003556120 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10499791 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002805884 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002805884 Country of ref document: EP |